Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Champions Oncology, Inc. (NASDAQ: CSBR) is a global oncology-focused technology and services company operating within the biotechnology research services and contract research organization (CRO) industries. The company provides translational research solutions that support oncology drug discovery and development for biopharmaceutical companies, academic institutions, and cancer research organizations. Its core offerings center on proprietary patient-derived tumor models and advanced data platforms designed to improve the predictability of cancer therapeutics.
The company’s primary revenue drivers are preclinical oncology research services and licensing or subscription-based access to its data and analytics platforms. Champions Oncology is uniquely positioned through its extensive bank of patient-derived xenograft (PDX) and ex vivo tumor models, which are marketed as being more clinically relevant than traditional cell-line-based approaches. Founded in 2007, the company has evolved from a model-focused research provider into an integrated oncology data and services platform, expanding capabilities through internal development and targeted acquisitions.
Business Operations
Champions Oncology operates through two primary business segments: Research Services and Data & Technology Solutions. The Research Services segment generates revenue by providing customized preclinical oncology studies, including in vivo and ex vivo testing, biomarker analysis, and pharmacology services using proprietary tumor models. The Data & Technology Solutions segment includes software platforms and curated oncology datasets that enable drug developers to benchmark compounds, analyze tumor response patterns, and support clinical decision-making.
Operations are conducted in both domestic and international markets, with laboratory and research facilities in the United States and Europe. The company controls a large library of proprietary PDX and tumor organoid models, as well as associated genomic and clinical annotation data. Champions Oncology operates through subsidiaries including Champions Oncology Srl and Champions Oncology UK Limited, which support its European research and commercial activities. No material joint ventures have been disclosed in public filings.
Strategic Position & Investments
Champions Oncology’s strategic direction is focused on expanding its oncology data ecosystem, increasing recurring revenue from technology platforms, and deepening relationships with biopharmaceutical clients across the drug development lifecycle. Growth initiatives include expanding its tumor model library, enhancing artificial intelligence–driven analytics, and integrating multi-omic datasets to improve translational relevance.
The company has pursued selective acquisitions to strengthen its technology stack and data assets, including the acquisition of Cell Line Genetics, which expanded its biomarker and genomic testing capabilities. Champions Oncology is also investing in emerging areas such as immuno-oncology modeling, combination therapy evaluation, and precision medicine analytics. Public disclosures do not indicate material equity investments in unrelated portfolio companies; growth has primarily been organic and bolt-on in nature.
Geographic Footprint
Champions Oncology is headquartered in Hackensack, New Jersey, and maintains a significant operational presence in North America and Europe. Its U.S. operations serve as the primary hub for corporate management, research services, and client engagement, while European facilities support in vivo and ex vivo oncology studies for regional and global customers.
The company serves clients across North America, Europe, and parts of Asia-Pacific, with international customers representing a meaningful portion of revenue. While Champions Oncology does not disclose country-level revenue concentration in detail, public filings confirm a diversified global customer base within the biopharmaceutical and oncology research sectors.
Leadership & Governance
Champions Oncology is led by an executive team with experience in oncology research, biotechnology services, and life sciences commercialization. The leadership emphasizes data-driven decision-making, scientific rigor, and improving the translational success rate of oncology drug development.
Key executives include:
- Ronnie Morris – President and Chief Executive Officer
- Dr. Gil Van Bokkelen – Chairman of the Board
- Mandy DeMichele – Chief Financial Officer
- Dr. Charles O. Riveros – Chief Scientific Officer
- Joel Lichtenstein – General Counsel and Corporate Secretary
The board and management team oversee corporate governance in accordance with U.S. public company standards, with strategic oversight informed by oncology research expertise and capital markets experience.